University of Miami Health System DaVita

University of Miami Health System DaVita appears in the evidence not as a generic healthcare label but as a defined dialysis-system setting for studying the consequences of hepatitis C virus infection. Its importance lies in the population data generated there: among patients undergoing long-term dialysis, anti-HCV antibody positivity was associated with higher all-cause mortality and higher cardiovascular mortality after adjustment for several patient characteristics.

Institutional Setting and Study Population

University of Miami Health System DaVita is presented as the system in which a population-based survey examined 2,778 patients receiving long-term dialysis. The evidence does not describe the organization’s internal structure, leadership, or clinical programs, but it does establish the system as a large dialysis-care environment capable of supporting outcome research across a clinically complex population.

The study used anti-HCV antibody serologic status as the principal exposure measure. That distinction matters: anti-HCV positivity indicates prior exposure or infection-related serologic evidence, whereas active chronic HCV infection requires both anti-HCV antibodies and detectable HCV RNA. The DaVita analysis therefore addressed the relationship between serologic status and outcomes, rather than independently proving active viremia in every patient classified as anti-HCV positive.

Mortality Findings

In the DaVita population, anti-HCV antibody positivity was associated with a hazard ratio of 1.28 for all-cause mortality, with a 95% confidence interval of 1.02–1.62 and a p value of 0.03, after adjustment for several case-mix parameters. The finding placed HCV serologic status within the broader risk profile of long-term dialysis patients rather than treating it as an isolated liver abnormality.

The association was stronger for cardiovascular death. The hazard ratio for cardiovascular mortality was 1.48, with a 95% confidence interval of 1.05–2.08 and a p value of 0.02. After adjustment for available surrogates of malnutrition-inflammation syndrome, the association was partly attenuated, to a hazard ratio of 1.43 with a 95% confidence interval of 1.00–2.06 and a p value of 0.05. This partial attenuation suggested that nutritional and inflammatory conditions may account for part, but not necessarily all, of the observed cardiovascular risk.

The relationship remained especially visible among younger dialysis patients. In the subgroup younger than 65 years, comprising 1,551 patients, anti-HCV positivity continued to be associated with cardiovascular mortality after adjustment for case-mix and malnutrition-inflammation covariates, with a hazard ratio of 1.80, a 95% confidence interval of 1.1–2.95, and a p value of 0.02. The subgroup result gave the DaVita findings a sharper contrast: the excess cardiovascular risk was not simply an artifact of the oldest or most medically fragile patients.

Subsequent Evidence and Wider Significance

The evidence also records a subsequent survey of 13,664 patients receiving regular dialysis and followed for three years. In that analysis, HCV antibody positivity was associated with a hazard ratio of 1.25 for three-year all-cause mortality, with a 95% confidence interval of 1.12–1.39 and a p value of 0.001. Although the relative risk of cardiovascular-disease mortality persisted across almost all patient groups, it did not reach statistical significance in every group.

Findings from outside the DaVita system pointed in the same direction. Another population-based study reported a hazard ratio of 1.34 for cardiovascular death among anti-HCV-positive patients after accounting for age, pre-existing cardiovascular disease, and other patient characteristics. A broader dialysis study likewise found an independent association between positive anti-HCV antibody status and mortality, with an adjusted relative risk of 1.17. Together, these comparisons made the DaVita result part of a converging evidence base rather than an isolated institutional observation.

Clinical Interpretation

The evidence connects the observed cardiovascular risk with several possible pathways. HCV-infected dialysis patients had lower serum albumin levels than their noninfected counterparts in a large United States survey: 3.68 ± 0.45 versus 3.76 ± 0.41 g/dl, respectively. Chronic infection may contribute to inflammation and poorer nutritional status, while HCV has also been associated with liver steatosis, insulin resistance, and hypoadiponectinemia. These factors may interact with conventional dialysis-related cardiovascular risks such as hypertension and hypercholesterolemia.

University of Miami Health System DaVita therefore functions in the book as an evidentiary site where HCV is linked to outcomes extending beyond the liver. The system’s contribution is the documentation of an adjusted association between anti-HCV serologic positivity and both overall and cardiovascular mortality in long-term dialysis, reinforcing the need to treat HCV as a condition with renal, metabolic, inflammatory, and survival consequences.